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Introduction
Acute life-threatening situations cause an intense stress 
response. Th  ese situations promote immuno-inﬂ  amma-
tory and metabolic responses that are entangled in an 
intricate way, as the cells involved in these key events 
onto  genetically originate from a unique primordial organ 
combining both immune and metabolic functions, 
namely the ‘fat body’ [1]. Acute stress-induced hypergly-
caemia [2] is observed in many conditions, such as 
myocardial infarct [3], and shock states, especially septic 
[4], but also traumatic [5], as well as stroke [6]. Th  e 
observed concordance between elevated blood glucose 
and mortality raised the question of a causative relation-
ship between hyperglycaemia and prognosis [7].
A landmark monocenter study published in 2001 
suggested that hyperglycaemia has a deleterious impact 
on prognosis in mostly surgical ICU patients, since tight 
glucose control by intravenous insulin dramatically 
improved mortality [8]. Th  e large debate following this 
publication questioned the population studied (mainly 
cardiovascular surgical patients), the respective roles of 
glycaemia control versus additional insulin, and the 
impact of the amount of exogenous carbohydrate [9]. In 
2006, the same group published another study performed 
on medical ICU patients testing the same protocol used 
in the ﬁ  rst study [10]. In this new study, global mortality 
did not improve with tight control of glycaemia and a 
worsening of the death rate in a subgroup of patients 
staying less than 3 days in the ICU was observed. Th  e 
group treated with tight control of glycaemia for more 
than 3 days had a reduction in severity and number of 
organ failures, which surprisingly did not translate to 
outcome beneﬁ   t. Subsequent ICU trials published 
recently [11-15] have failed to conﬁ  rm a beneﬁ  t of tight 
control of glycaemia on prognosis in critically ill patients 
while emphasizing the potential role of hypoglycaemia in 
explaining the divergent results.
Th  e recently published meta-analysis by Marik and 
Preiser [9] showed that, overall, tight glycaemic control 
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The physiological response to blood glucose elevation is the pancreatic release of insulin, which blocks hepatic 
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© 2010 BioMed Central Ltddid not reduce 28-day mortality (odds ratio (OR) 0.95; 
95% conﬁ  dence interval (CI), 0.87 to 1.05), the incidence 
of blood stream infections (OR 1.04; 95% CI, 0.93 to 
1.17), or the requirement for renal replacement therapy 
(OR 1.01; 95% CI, 0.89 to 1.13). Th   e incidence of hypo-
glycaemia was signiﬁ  cantly higher in patients randomized 
to tight glycaemic control (OR 7.7; 95% CI, 6.0 to 9.9; 
P < 0.001). Metaregression demonstrated a signiﬁ  cant 
relationship between the 28-day mortality and the 
proportion of calories provided parenterally (P = 0.005), 
suggesting that the diﬀ  erence in outcome between the 
two Leuven Intensive Insulin Th  erapy Trials and the 
subsequent trials could be related to the use of 
parenteral nutrition. More importantly, when the two 
Leuven Intensive Insulin Th   erapy Trials were excluded 
from the meta-analysis, mortality was lower in the 
control patients (OR 0.90; 95% CI, 0.81 to 0.99; P = 0.04; 
I(2) = 0%).
Th   e focus of this review is an integrative description of 
the main pathways and mechanisms involved in the acute 
stress conditions responsible for hyperglycaemia, and the 
description of complex situations involving both the 
stimulation of systemic inﬂ   ammation and changes in 
metabolic requirements [16] in an attempt to clarify 
apparent contradictory results.
Metabolic pathways using glucose during acute 
critical conditions
Th   e normal response to a stress situation associates the 
activation of central nervous system and neuroendocrine 
axes with increased release of hormones such as cortisol, 
macrophage inhibiting factor (MIF) [17,18], epinephrine 
and norepinephrine, growth hormone, and glucagon. 
Th  ese hormones profoundly modify the inﬂ  ammatory 
response, especially cytokine release. Stress hormones 
generate globally a systemic pro-inﬂ  ammatory  proﬁ  le 
while anti-inﬂ   am  mation is predominant at the tissue 
level (for a review, see [19]). Th   ese hormones, except for 
MIF, also stimu  late, among other mechanisms, gluco  neo-
genesis and hepatic glucose production, thus aggravating 
hypergly caemia  [20].
Th  e pancreatic insulin release in response to blood 
glucose elevation leads to the blocking of hepatic glucose 
production and the stimulation of glucose uptake and 
storage by the liver, muscle and adipose tissue. If this ﬁ  rst 
line of regulation fails to control glucose levels, the 
micro  environment of cells will contain high levels of 
glucose. To enter the cell, glucose uses transporters that 
allow facilitated diﬀ  usion (via concentration gradients) 
through the cytoplasmic membrane. Th  ese transporters 
are part of the superfamily of  glucose transporters 
encoded by the GLUT genes; there are several isoforms, 
such as GLUT4, and their expression on the cell surface 
is ampliﬁ  ed by insulin [21].
After entering the cell, glucose may go through diﬀ  er-
ent metabolic pathways in addition to glycolysis, as 
summarized in Figure 1. During the early hours of stress, 
the metabolic stimulation of the cell corresponds to 
increased mitochondrial energy production (ATP) with 
increased O2 and glucose consumption [22]. Similarly, 
during cell proliferation, glucose availability is necessary 
for the induction of glycolytic enzymes, such as hexo-
kinase, pyruvate kinase or lactate dehydrogenase. Th  is 
glycolysis favours lactate production despite O2 
availability [23], and regeneration of NAD+, which is 
required for additional cycles of glycolysis [24].
Recognition and cellular mechanisms of acute conditions
Acute critical conditions cause cellular injuries that are 
known to initiate repair or cell death pathways (Figure 2). 
Th   ese integrative mechanisms tend to either contain the 
response at the local level or, on the contrary, spread it by 
recruiting circulating cells and factors for repair.
Damaged cells communicate with innate immune cells 
by releasing intracellular factors named damage-asso-
ciated molecular pattern molecules (DAMPs), such as 
calgranulines [25] and alarmines [26,27] (Figure 2). Together 
with pathogen-associated molecular pattern molecules 
(PAMPs), they activate the cellular expression of Toll-like 
receptors (TLRs) [28]. Accumulation of abnormal 
proteins, which are processed by the proteasome S26 
system in the endoplasmic reticulum [29], as well as 
ﬂ  uctuations of nutrients or energy availability, hypoxia, 
viruses and toxins activate a complex transcriptional 
response called the endoplasmic reticulum stress response 
(Figure 2), or the unfolded protein response [30].
Receptors for recognition of inﬂ  ammation appear on 
both target cells and inﬂ  ammatory cells. Th   e alteration of 
the extracellular milieu is transmitted into the cell, 
modifying its functions. In peripheral blood mononuclear 
cells, for instance [31], an increased energy demand 
associated with a simultaneous metabolic failure can 
occur [32,33]. Th   e increased permeability of the injured 
mitochondria leads to energy loss and cell death, which 
by itself fuels the inﬂ   ammatory process through the 
release of the cell contents.
Injuries due to cellular environment
Hypoxia
Hypoxia induces hypoxia-inducible factors (HIFs), O2-
sensing transcription factors that regulate the transcrip-
tion of genes [34] encoding numerous molecules involved 
in vascular reactivity, recruitment of endothelial pro-
genitors, and cytoprotection [35,36]. During hypoxia 
(Figure 3), liver and skeletal muscle glycogenolysis is 
stimulated, increasing glucose availability [37]. Increased 
expression of GLUTs on any cell type [38-40] is mediated 
by the activation of AMP kinase and p38 
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cellular redox status [41,43].
While glycolysis is activated by hypoxia, phospho-
fructokinase-1 and lactate dehydrogenase activity is 
stimu  lated by increased lactate production [44] 
associated with decreased mitochondrial oxygen con-
sump tion.  Th  is mechanism, described since 1910 in 
tumour cells as the ‘Warburg  eﬀ  ect’ [45], seems to be 
adaptive to the lack of oxygen while maintaining cell 
redox status. A suﬃ     cient amount of energy is then 
produced but without an increase in reactive oxygen 
species (ROS) production by the mitochondria [46].
Adenosine
Adenosine production mainly results from ATP degrada-
tion during stress when it is released into the extracellular 
space. Adenosine regulates innate and adaptive immune 
functions by interacting with almost every immune cell 
Figure 1. Overview of glucose metabolism in mammalian cells. Glucose is known to be oxidized through cytoplasmic glycolysis to produce 
pyruvate. Pyruvate may be reduced into lactate by lactate dehydrogenase or it may enter the mitochondria to participate in the citric acid cycle and 
the production of ATP by the mitochondrial respiratory chain and ATPase. However, glucose can be involved in other pathways. Glycogen synthesis 
is a major way to store glucose in muscle and liver. In the polyol pathway, aldose reductase reduces toxic aldehyde to inactive alcohol and glucose 
to sorbitol and fructose. In reducing NADPH to NADP+, this enzyme may be deleterious by consuming the essential cofactor needed to regenerate 
reduced glutathione, an essential antioxidant factor in cells. The hexosamine pathway originates from glycolysis at the fructose-6-phosphate level. 
In this pathway, glutamine fructose-6-phosphate amidotransferase is involved in the synthesis of glucosamine-6-phosphate, which is ultimately 
converted to uridine diphosphate (UDP)-N-acetyl-glucosamine. This glucosamine is able to activate transcription factors such as Sp-1 and to 
induce the production of pro-infl  ammatory cytokines. Diacylglycerol, which activates isoforms of protein kinase C (PKC), may be produced from 
dihydroxyacetone phosphate. The PKC activation can induce several pro-infl  ammatory patterns, such as activation of the transcription factor NF-κB, 
and the production of NADPH oxidase or pro-infl  ammatory cytokines. The pentose phosphate pathway may use glucose-6-phosphate to produce 
pentoses for nucleic acid production. This pathway is also able to produce NADPH for use in lipid, nitric oxide and reduced glutathione production, 
and also the synthesis of reactive oxygen species by NADPH oxidase. Advanced glycation end product (AGE) synthesis is linked to high intracellular 
glucose concentrations. AGEs can induce cell dysfunction by modifying cell proteins, and extracellular matrix proteins, which changes signalling 
between the matrix and the cell, or by activating receptors for advanced glycation end products (RAGEs), which induce the production of the 
transcription factors NF-κB and TNF-α or other pro-infl  ammatory molecules. GLUT, glucose transporter.
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cytokine production and immune cell proliferation, and 
participates in tissue repair and remodelling. Adenosine 
induces increased intracellular cAMP, which stimulates 
protein kinase (PK)A, which in turn activates the trans-
cription factor CREB (cAMP response element-binding), 
thus linking the inﬂ  ammatory response to alterations of 
glucose metabolism [48].
Oxidative stress
Oxidative stress produces ROS, which alter normal cell 
function. ROS are permanently released at a low rate at 
the cytoplasmic membrane (NADPH oxidase, myelo-
peroxidase, cyclooxygenase) and in the cytoplasm (heme 
oxygenase, xanthine oxidase), and also within the mito-
chondria. When activated, phagocytic cells display a 
speciﬁ  c response called the ‘respiratory burst’, which is an 
acute overproduction of ROS by the activation of the 
NADPH oxidase Nox 2. Oxidative stress may indirectly 
modify glucose metabolism since it induces DNA altera-
tions that activate the nuclear enzyme poly-ADP-ribose 
polymerase 1 (PARP-1). Th   is activation consumes NAD+ 
and depletes its intracellular stores, which in turn 
hampers glycolysis and ATP production, in parallel with 
altered cell functions [49]. A transient low level of 
oxidative stress with redox alterations stimulates glucose 
uptake via insulin-independent GLUT transporters 
mediated by the AMP kinase pathway [50,51].
Figure 2. Integration of stress-signalling mechanisms. Damaged or dysfunctioning cells communicate with innate immune cells by releasing 
intracellular factors named damage-associated molecular pattern molecules (DAMPs). During cell death, these molecules, such as calgranulines 
from the protein S100 A superfamily or alarmines such as the nuclear protein high-mobility group box 1 (HMGB1), are released into the extracellular 
space to activate the immune system. These molecules associate with pathogen-associated molecular pattern molecules (PAMPs) from destroyed 
pathogens to activate cellular expression of Toll-like receptors (TLRs) of the pattern recognition receptor (PRR) superfamily. Some of these 
receptors, specifi  cally TLR2, 4 and 9, recognize multiple DAMPS released during stress and cell death. Proteins with abnormal conformation are 
processed by the proteasome S26 system in the endoplasmic reticulum, where protein kinase R-like endoplasmic reticulum kinase (PERK)-type 
kinases are activated; these pathways depend on Ire1 (which requires inositol) and nuclear factors, such as NF-κB and Nrf2 (NF-E2 related factor). 
Nrf2 controls the expression of genes encoding enzymes that remove reactive oxygen species (ROS), including heme oxygenase 1 (HO-1) and 
glutathione S-transferase (GST). PERK-dependent phosphorylation of Nrf2 thus coordinates a transcriptional program connecting oxidative stress 
and endoplasmic reticulum stress. Activation of the transcription factor CREB-H can be achieved through this endoplasmic reticulum stress; CREB-H 
is responsible for the acute infl  ammatory response in the liver with acute phase protein synthesis. Adapted from [1]. GLUT, glucose transporter; HIF, 
hypoxia-inducible factor; HO, heme oxygenase; IKK, IκB kinase; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; NOS, nitric oxide synthase; PKC, 
protein kinase C; RAGE, receptors for advanced glycation end products; ssRNA, single-stranded RNA.
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Sepsis corresponds to a systemic inﬂ  ammation related to 
the abnormal presence of bacterial antigens and involves 
diﬀ   erent mechanisms such as hypoxia and oxidative 
stress. At the early phase, inhibition of glycogen synthesis 
results in increased global glucose availability and 
increased cellular uptake [52-54]. Glucose uptake appears 
to be most increased in organs containing a vast 
population of phagocytic cells (liver, spleen, gut, lung) 
[55-57]. In rats injected with endotoxin or TNF-α, 
insulin-independent glucose uptake is increased in liver 
non-parenchymal cells (Küpﬀ  er cells, endothelial cells) 
[58], as observed in circulating immune cells, including 
polymorphonuclear leukocytes [59,60], lymphocytes, 
monocytes and macrophages [61-63]. Skeletal muscle 
displays only a limited increase in glucose uptake, probably 
because of the development of insulin resistance.
Sepsis also modiﬁ  es cytoplasmic glycolysis at the trans-
criptional level. In healthy volunteers receiving intra-
venous endotoxin, there was an early under-expression of 
genes encoding metabolic enzymes [64]. In particular, 
the key enzymes of glycolysis and those of the 
Figure 3. Role of hypoxia in cell metabolic reprogramming. Hypoxia-inducible factors (HIFs), O2-sensing transcription factors, regulate the 
transcription of genes encoding Heme-oxygenase-1 (HO-1), erythropoietin (EPO), and numerous molecules involved in vascular reactivity (such 
as nitric oxide synthase (NOS)), recruitment of endothelial progenitors, and cytoprotection through angiogenic growth factors such as vascular 
endothelial growth factor (VEGF). During hypoxia, glycogenolysis is stimulated, increasing glucose availability. An increase in glucose transporter 
(GLUT) expression enables augmented glucose uptake. This overexpression of GLUTs is mediated by the activation of AMP kinase (AMPK) and p38 
mitogen-activated kinase. Stimulation of AMPK results from a decreased cytoplasmic ATP/AMP ratio together with altered cellular redox status. 
Phosphofructokinase-1 and lactate dehydrogenase activity is stimulated by increased lactate production. HIF decreases mitochondrial oxygen 
consumption and induces the expression of pyruvate dehydrogenase kinase, the main inhibitor of pyruvate dehydrogenase and of the entry of 
acetylCoA into mitochondria. Adapted from [36]. OXPHOS, oxidative phosphorylation; TGF, transforming growth factor.
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under-expressed. In the diaphragm of septic rats, 
transcription, synthesis and activity of the constituents of 
the MRC, as well as of phosphofructokinase-1, a key-
enzyme of glycolysis, are reduced [65]. In muscle of 
septic rats, the activity of pyruvate dehydrogenase is 
reduced, with a simultaneous increase in the activity of 
its inhibitor, pyruvate dehydrogenase kinase. Th  e net 
result of these modiﬁ  cations is a reduction in pyruvate 
entering the mitochondria while the conversion of 
pyruvate to lactate is promoted [66].
In septic shock patients, increased use of glucose and 
increased lactate production was observed under aerobic 
conditions [67]. A microdialysis study of quadriceps 
muscles showed lactate overproduction during septic 
shock resulting form exaggerated aerobic glycolysis 
through Na/K-ATPase stimulation. To maintain cell 
func  tions, stimulation of glycolysis was shown to adap-
tively compensate for the metabolic rate increase [68]. 
Elevated circulating epinephrine stimulates Na/K-ATPase, 
which promotes lactate hyperproduction without any 
oxygen debt [69].
Mitochondrial dysfunction during sepsis [70] involves 
alterations in the structure [71] and function of the MRC, 
including impairment of key enzymes of electron 
transport and ATP synthesis [72,73] and mitochondrial 
biogenesis [74]. Th  ese results were also found with 
monocytes [75] and skeletal muscle [76] harvested from 
septic shock patients. ATP levels in skeletal muscle cells 
were main  tained despite mitochondrial ultrastructural 
alterations [76]. Th  is mitochondrial dysfunction results 
from plasmatic factors that promote uncoupled MRC 
oxygen consumption [77] that correlates with sepsis-
induced modiﬁ  cations of the immune phenotype and is 
associated with increased mitochondrial permeability [78].
In summary, glucose metabolism alterations in acute 
critical conditions can be viewed as a ‘redistribution of 
glucose consumption away from mitochondrial oxidative 
phosphorylation’ towards other metabolic pathways, 
such as lactate production. Th   is re-channelling does not 
seem to aﬀ  ect energy supply to the cells. Th   is may result 
from decreased ATP consumption by the cells, which in 
turn lose some of their characteristics, indicating 
metabolic failure [79].
Why does glycaemia fi  nally increase during acute 
injury?
Stress-induced hyperglycaemia results from the com-
bined eﬀ  ects of increased counter-regulatory hormones 
that stimulate glucose production and reduced uptake 
associated with insulin resistance, that is, decreased 
insulin activity. Th  ere is also inadequate pancreatic 
insulin release with regard to glycaemia (or adaptive 
‘pancreas tolerance’). Insulin release during stress is 
decreased mainly through the stimulation of α-adrenergic 
pancreatic receptors [20]. Pro-inﬂ  ammatory  cytokines 
may directly inhibit insulin release by β pancreatic cells 
[80]. A new glucose balance results, allowing a higher 
blood ‘glucose pressure’, which aﬀ  ects tissues diﬀ  erently 
depending on whether they are insulin-dependent or not.
Glucose availability also relies on delivery to cells, 
analogous to oxygen diﬀ  usion. For glucose to arrive at a 
cell with reduced blood ﬂ  ow (ischemia, sepsis), it must 
move from the blood stream across the interstitial space. 
Glucose movement is dependent entirely on a concen-
tration gradient, and for adequate delivery to occur 
across an increased distance, the concentration at the 
origin (blood) must be greater. Th   erefore, in the face of 
reduced or redistributed blood ﬂ  ow, hyperglycaemia is 
adaptive.
Development of insulin resistance
Insulin resistance (IR) is a reduction in the direct eﬀ  ect of 
insulin on its signalling process leading to metabolic 
consequences [81], very similar to type 2 diabetes, and is 
commonly observed during sepsis [82].
Insulin acts mainly on the liver, muscle and fat (meta-
bolic eﬀ  ects), but it also targets many cellular subtypes to 
stimulate essentially protein and DNA synthesis as well 
as apoptosis (mitogenic eﬀ   ects). Hepatic IR involves 
increased hepatic glucose production (gluconeogenesis) 
together with decreased glycogen synthesis. During 
sepsis, however, gluconeogenesis can be limited by inhi-
bi  tion of important enzymes [83,84]. Muscle IR corres-
ponds to decreased glycogen deposition and glucose 
uptake linked to decreased expression of GLUT4, while a 
transient defect in insulin signalling has also been 
described [85]. IR in adipocytes leads to inhibition of 
lipogenesis and activation of lipolysis.
The main mediators
Pro-inﬂ   ammatory cytokines (IL-6, TNF-α), as well as 
endotoxins via TLR4, participate in the development of 
IR by stimulating hepatic glucose production [86] and 
altering insulin signalling [87]. Th  ese cytokines activate 
numerous kinases that inhibit insulin signal transduction 
[88-91]. TNF-α has been shown to induce the expression 
of SOCS-3 (Suppressor of cytokine signalling-3), which 
speciﬁ  cally inhibits insulin receptor phosphorylation [92].
MIF is not only produced by various immune cells [93] 
and the anterior pituitary gland, but also by islet β cells, 
where it positively regulates insulin secretion [94]. 
During inﬂ  ammation in skeletal muscle, locally produced 
MIF stimulates glucose use and lactate production [95]. 
In endotoxemic mice genetically deﬁ  cient in MIF, glucose 
metabolism is almost normalized when compared to 
wild-type mice [96]. Increased circulating cortisol parti-
ci  pates in the maintenance of blood glucose not only by 
Losser et al. Critical Care 2010, 14:231 
http://ccforum.com/content/14/4/231
Page 6 of 12increasing its production or decreasing its utilization, but 
also by directly inhibiting insulin secretion by ß cells [97].
Endogenous catecholamines are also involved in the 
alteration of glucose metabolism during endotoxaemia 
[98], especially in the liver [99]. Exogenous epinephrine 
metabolic eﬀ   ects on glucose turnover were, however, 
attenuated in endotoxic rats when compared to controls 
[100].
Role of exogenous glucose supply and induced 
hyperglycaemia
Glucose acts not only as an energetic substrate but also as 
a signalling molecule of the cellular environment, as 
shown in diabetes with chronic hyperglycaemia. Stress-
induced acute hyperglycaemia has been less studied up to 
now as it has been considered an adaptive response. 
Some concepts from chronic hyperglycaemia may, how-
ever, be used in acute conditions. Intravenous adminis-
tration of exogenous glucose yielded similar glycaemia in 
control and septic animals despite higher insulin levels in 
the septic group [101]. Hepatic glycogen deposition was 
observed only when glucose was infused via the portal 
vein [31,102].
Glucose-controlled genomic modifi  cations
In fasted animals, increased circulating glucagon induces 
a gluconeogenic program by activating the nuclear trans-
ription factor CREB through a molecule named Crtc2 
(CREB regulated transcription coactivator 2) or TORC 2 
(Transducer of regulated CREB activity 2) [103,104]. Th  e 
expression rate of gluconeogenic enzymes is thus 
increased, especially for glucose-6-phosphatase.
Re-feeding in turn increases insulin levels, which 
inhibits hepatic glucose production partly by ubiquitin-
dependent destruction of Crtc2 [105]. During sustained 
hyperglycaemia, the hexosamine pathway can be acti-
vated [106]. In hepatocytes, Crtc2 is then O-glycosylated 
on a serine residue instead of being phosphorylated. It 
can thus migrate into the nucleus to activate CREB and 
the gluconeogenic program, contributing to maintain 
hyperglycaemia [107]. Th  is has been described as the 
‘sweet conundrum’ [105]. Regulation of this pathway 
during acute injury remains to be proven.
Hyperglycaemia and the infl  ammatory response
In diabetics, glucose channelling through alternative 
glycolytic pathways seems to depend on MRC activity 
[106,108]. Th   e accumulation of energy substrates induced 
by isolated hyperglycaemia without a concomitant 
increase in energy demand may enhance the ﬂ  ux  of 
carbon hydrates to the mitochondria with increased 
activity of the MRC and proton driving force. Once the 
activity of ATPase is saturated, intermediate radicals 
from the MRC will accumulate and may react with the 
surrounding available O2 to produce ROS [109], as shown 
in bovine endothelial cells. When inhibiting this radical 
production, the activity of alternative glycolytic pathways 
is decreased as well as the expression of transcription 
factor NF-κB [110]. Inhibition of glyceraldehyde-3-phos-
phate dehydrogenase, an enzyme involved in cytoplasmic 
glycolysis, has also been observed. Metabolites accumu-
late upstream of this enzyme and are funnelled towards 
alternative pathways (Figure 1). Polymers of ADP-ribose, 
produced by nuclear PARP to repair DNA altered by 
mitochondrial ROS, may be involved in this inhibition. 
PARP, by migrating into the cytosol, may be a key to 
glucose toxicity [111]. Th   ere is still a lack of evidence to 
fully extrapolate these theories to explain mitochondrial 
dysfunction and organ failure observed during stress-
induced hyperglycaemia.
Glucose also acts as a pro-inﬂ  ammatory  molecule 
[81,112]. Glucose ingestion in healthy volunteers rapidly 
increases the activity of NF-κB [113] and the production 
of mRNA for TNF-α [114]. Under the same conditions, 
acute hyperglycaemia increased the activity of the trans-
cription factors AP-1 (Activator protein-1) and EGR-1 
(Early growth response-1), which in turn activate the 
production of matrix metalloproteinase-2 (MMP-2) by 
monocytes, an enzyme that facilitates the diﬀ  usion of 
inﬂ  am  mation by hydrolysing extracellular matrix. Pro-
duc  tion of tissue factor, a prothrombotic and proaggre-
gant molecule [115], is increased, as is production of 
cellular adhesion molecules [116]. Acute hyperglycaemia 
induced in healthy volunteers by octreotid, an inhibitor 
of insulin release, leads to a rapid and transient secretion 
of pro  inﬂ  ammatory cytokines (IL-6, TNFα, IL-8). Th  is 
eﬀ   ect is ampliﬁ   ed in insulin-resistant subjects and 
blunted with antiradical treatment [117].
Glucose-cytokine interactions
In vitro, an increased release of IL-1ß has been measured 
in the culture medium of human monocytes exposed to 
hyperglycaemic conditions after endotoxin stimulation 
[118]. In our model of endotoxaemia [102], glucose 
supply interfered with haemodynamic, metabolic and 
inﬂ   am  matory responses, with a dramatic increase in 
circulating TNF-α when intraportal glucose was adminis-
tered. Fasting on the other hand seemed to attenuate the 
response to endotoxin.
In liver transplant patients, glucose feeding during the 
early postoperative period induced major haemodynamic 
modiﬁ   cations within the graft, where the immuno-
inﬂ  ammatory insult occurs [119], including almost halted 
arterial hepatic inﬂ  ow. Th  is vasoconstriction was speci-
ﬁ  cally related to glucose since fructose, amino acids and 
fatty acids did not provoke this eﬀ   ect. One tempting 
hypothesis for this eﬀ  ect involves increased production 
of ROS, which are well known to vasoconstrict arteries.
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Nutrients, and especially glucose, are able to stimulate 
oxidative stress and inﬂ  ammatory responses [106]. Th  e 
body thus needs to regulate nutrient excesses in order to 
maintain metabolic homeostasis. STAMP2 (Six-trans-
membrane protein of prostate 2) has recently been 
detected in adipose tissue, a key organ in the management 
of nutrient excesses, and is also expressed in the heart, 
liver, lung and platelets [120]. In STAMP2 genetically 
deﬁ  cient mice, the eﬀ  ects of insulin on liver, muscle and 
adipose tissue are altered, all three being essential organs 
for glucose homeostasis. STAMP2 is a metalloreductase 
involved in iron handling, which may inﬂ  uence  ROS 
production [121]. Ingestion of glucose in healthy volun-
teers led to increased production of ROS in circulating 
monocytes and polymorphonuclear leukocytes. Th  is  was 
associated with the rapidly increased synthesis of 
NADPH oxidase subunits [122].
Th  ese data suggest that glucose induces profound 
modi ﬁ     cations of the monocyte pro-inﬂ  ammatory  res-
ponse. In peripheral blood mononuclear cells harvested 
from healthy volunteers and septic patients [77,123], 
increasing extracellular glucose increased glucose uptake. 
Subsequent stimulation of these cells by various agonists 
increased ROS production via NADPH oxidase in both 
the healthy volunteers and the septic patients. Th  e link 
between ROS and intracellular glucose levels could be 
the increased production of NADPH via the pentose 
phosphate cycle [123] (Figure 4). More studies are needed 
to conﬁ  rm these multifaceted eﬀ  ects and to conﬁ  rm that 
such a coordinated regulation between nutrient availa-
bility and the intensity of the inﬂ  ammatory response is 
also at play during acute insults. To cite Leverve, ‘it 
appears that glucose obviously plays a very subtle role in 
oxidant cellular signaling. It can either increase or 
decrease ROS production and can either increase or 
decrease the antioxidant defense […]. Th   erefore it is not 
surprising that any change in blood glucose must be 
considered as a complex event, and taking care of gly-
cemia and redox homeostasis will be probably central in 
the management of ICU patients in the next years’ [124].
Recent in vitro data suggest that giving glucose boluses 
after hypoglycaemia may trigger neuronal death due to 
ROS overproduction [125]. In healthy volunteers, hyper-
glycaemic spikes induced increased pro-inﬂ  ammatory 
cytokine levels that were blunted by antioxidant pre-
treatment [117]. Th  is introduces the concept of glucose 
variability, which by itself seems to be deleterious with 
regard to outcome in critically ill patients [126,127].
Future prospects
Many questions regarding glycaemia remain to be solved 
for daily critical care practice. How should we achieve 
gly  caemic control: should we take into account 
nutritional support, especially parenteral nutrition [9]? 
Should we control the physiological response to an 
induced hyper  glycaemia or should we control the 
endogenous stress-induced hyperglycaemia that may be 
adaptive in the absence of exogenous glucose intake? Is 
there a place for new therapeutics such as incretins [128]? 
Does endogenous hyperglycaemia have a similar impact 
as hyperglycaemia induced by nutritional support? Th  ese 
questions in turn prompt investigation of the role of 
glucose deprivation induced by fasting with regard to 
normoglycemia achieved by insulin therapy. Similarly, 
the consequences of spontaneous versus insulin-induced 
hypoglycaemia remain to be investigated. Answers to 
these questions will probably help to solve the conﬂ  ict 
between supporters and opponents of tight glycaemia 
control in the ICU. Th   is discussion is in accordance with 
the concerns raised by several authors about early 
initiation of parenteral nutrition in acute critical patients 
[129,130], as supported by the results of two large 
multicentre studies, Nice-Sugar [14] and Glucontrol [15].
Conclusion
Glucose metabolism is profoundly altered during acute 
conditions, from its uptake to the induction of complex 
programs of gene expression [14]. Th   e increased glucose 
availability in cells is not necessarily used to produce ATP 
by mitochondria. Glucose seems able to activate pro-
inﬂ  ammatory metabolic pathways. While chronic expo-
sure to these end products seems deleterious (diabetes), 
their actual roles during acute conditions need to be 
further elucidated. Early stress-induced hypergly  caemia 
has been described as an adaptive response that could in 
turn sustain an adaptive inﬂ   ammatory response (host 
Figure 4. Glucose and reactive oxygen species production 
during sepsis: hypothesis. In peripheral blood mononuclear cells 
harvested from healthy volunteers and septic patients, increasing 
extracellular glucose increased glucose uptake. Subsequent 
stimulation of these cells by various agonists, such as PMA (phorbol 
12-myristate 13-acetate), a protein kinase C (PKC) activator, increased 
reactive oxygen species (ROS) production via NADPH oxidase in both 
the healthy volunteers and septic patients. The link between ROS and 
intracellular glucose levels could be increased production of NADPH 
via the pentose phosphate pathway.
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Page 8 of 12defence, wound healing, and so on). Glucose intake-
induced hyper  glycaemia may, however, lead to 
maladjusted and disproportionate inﬂ  ammation  that 
should be avoided. How then should this subsequent 
hyper  glycaemia be prevented: should we limit glucose 
supply at the early phase of inﬂ  ammation?
Si quis febricitanti cibum det, convalescenti quidem, 
robur : ægrotanti verò, morbus ﬁ  t
Hippocrates [131]
(Food given to those who are convalescent from fever, 
increases strength; but if there be still disease, increases 
the disease)
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